Overexpression of α-Klotho or treatment with sKl inhibits insulin/IGF-1-mediated downstream effectors IRS-1, Akt1, and ERK1/2 in cancer cells (57, 59, 65, 67, 73–76). This evidence concerns the gene MAPK3 and cancer.